Bristol Myers Squibb’s Post

Cell therapy is increasingly becoming an impactful therapeutic alternative to traditional treatments for a variety of diseases. Achieve consistency, control, and a better understanding of your cell therapy processes today with 908 Devices' suite of purpose-built desktop devices. https://bit.ly/3SCz2j8 #celltherapy

Real progress is being made in bringing cell therapies closer to patients in their communities! That was the vision highlighted during the workshop “Moving Cell Therapy Closer to Patients – Delivering in the Community for the Community,” chaired by Sankalp Sethi, from ZS. One of my favorite insights came from Lee Buckler (Blood Centers of America): “If companies and hospitals can deliver curative therapies, the rest is engineering and business”. Agreed! Key takeaways from the panel emphasized standardization and scaling: Jonathon Paul DiTroia (McKesson): Standardization means letting go of some control for the greater benefit of the patient. • Lee Buckler (Blood Centers of America): Closed automated systems are the future. • Bryan Campbell (Bristol Myers Squibb): We need systems for remote monitoring and communication to improve continuity of care. We want the patients close to their homes and families. • Dr Mert Aral (Huma): We need technology to connect centers and communities, reducing relocation and stay costs for patients. • Shanna White, MD (Phoenix Children's Hospital): The industry can work together to develop simplified manufacturing and treatment processes that are easy to implement, for the benefit of patients. As the conference wraps up, we start reflecting on the exceptional experiences we have had and will share them with our community soon! It was great connecting with everyone! #Minerva #CellTherapy #BiotechInnovation #CGMesa24 #ManufacturingExcellence

Precision in cell therapy = better outcomes for patients. Our white paper explores how the Cue® Cell Processing System delivers exceptional accuracy, ensuring the integrity of cell therapies and paving the way for successful treatments. This is the future of personalized medicine. Read the white paper to learn more: https://lnkd.in/gZWPCiem #EfficientCellTherapy #Cue #CellProcessing #CellTherapyManufacturing #CellTherapy #CGT

Sequencing of Cell Therapies in Multiple Myeloma Continues Evolving https://lnkd.in/gPamFQBQ

📢 Calling all professionals in CAR-T research! Don't miss this webinar to gain exclusive insights on the latest industry knowledge and trends of CAR-T cell therapy. #CART #CancerTreatment #Immunotherapy #AtlantisBioscience

🎓 Are you a year or so into your career in transplantation & cellular therapies? The Clinical Education Conference has a special beginners' track designed just for you! Learn from case studies & grow your expertise. View the full agenda: https://ow.ly/7tHM50SkS57 #CEC24

“Mitigating patient identification errors from the get-go” Why has Epic become the gold standard of EMR so quickly? 1. It’s user friendly 2. It has the capacity to be a ‘care everywhere’ model 3. The information seamlessly flows to the right clinician at the right time Why is this important for the cell therapy field and, most importantly, patients? Watch the whole interview here https://hubs.ly/Q02Gmccf0

What's next for #stemcell therapy? Dr. Robert Negrin addresses three key areas of #CARTcell therapy on the brink of innovation >> https://bit.ly/4ghjMBI #Biorasi2024 #clinicaltrials

𝗕𝗲𝗵𝗶𝗻𝗱 𝘁𝗵𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲: 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗖𝗔𝗥 𝗧 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗔𝘂𝗴𝗺𝗲𝗻𝘁𝗲𝗱 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗗𝗲𝘀𝗶𝗴𝗻 Traditional phase 1 trials for CAR T cell therapy can be slow and resource-heavy. Our 𝗔𝘂𝗴𝗺𝗲𝗻𝘁𝗲𝗱 𝗗𝗲𝗳𝗶𝗻𝗶𝘁𝗶𝘃𝗲 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗗𝗲𝘀𝗶𝗴𝗻 (𝗗𝗦𝗗) streamlines this process, using advanced simulations to optimize dose combinations with fewer cohorts. The result? Up to a 2.37x higher chance of achieving a favorable benefit-risk profile, accelerating development and improving patient outcomes. 💡 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗠𝗼𝗿𝗲: Check out our ACoP poster: https://ow.ly/VMYt50Uk5PM 🧠 𝗖𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗼𝗿𝘀: Michael Dodds | Mirjam Trame | Leandro Pippa 🗓️ 𝗟𝗲𝘁’𝘀 𝗖𝗼𝗻𝗻𝗲𝗰𝘁: Book a complimentary 15-minute consultation: https://ow.ly/jL8850Uk5PN #ClinicalTrials #CancerResearch #PrecisionMedicine #InnovativeDesign #ACoP15

We often quote GEP Box on "all models are wrong; some are useful", but we do a terrible job bringing one of this great statistician's body of work to drug development: Design of Experiments. Sure, we do a little D-optimal design for sampling times, maybe a crossover study... but it's pretty primitive. Andrew Hooker, France Mentre, Stephen Duffull and others have suggested more ways to bring more DoE into clinical drug development, so I'm in good company with this effort. Basically, Definitive Screening Designs allow us to study N factors (dose, schedule, possibly important patient factors, etc.) at three levels each with 2*N+1 cohorts. These designs are incredibly dense (technically, "supersaturated"), can be analyzed using simple ANOVA approaches for significance testing, and support model-based analysis to boot. Our manufacturing colleagues are doing this already under Quality-by-Design auspices. We're late to the party, and our patients deserve better, faster, and more informative studies.